Promising results for Temodex, drug candidate against brain cancer, after completion of the first MGMT study

Preliminary results indicate that there is no significant difference in survival between MGMT methylation-positive and negative patients treated with Temodex, and that all patients who received Temodex had a significantly better survival than the control group when both DNA and protein data for MGMT were taken into account. This result will later this year be presented at scientific meetings and in scientific journals. Further studies on a larger group of patients are scheduled to start shortly. "MGMT status permits to distinguish patients who respond well or respond poorly to standard-